Insulin-like growth factor 1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
they are easy to consume and as such are convenient for such patients as "the elderly, stroke victims, bedridden patients, patients affected by kidney failure, and people who refuse to swallow, such as pediatric, geriatric, and psychiatric patients"; increased bioavailability (rapid absorption) due to pregastric absorption; don't require water to consume and thus suitable for "patient compliant for disabled, bedridden patients, and for travelers and busy people who do not always have access to water"; good mouth feel; improved safety due to low risk of choking or suffocation during oral administration.
Smuggling of fenethylline became Syria's principal export, exceeding the total of all other exports under the Assad regime during the Syrian civil war (2011–2024). It was the world's largest producer of the drug. A large quantity of Captagon tablets, ready for clandestine export, was captured by anti-Assad forces that took control of Damascus in December 2024.
Constipation refers to bowel movements that are infrequent or hard to pass. Constipation is a common cause of painful defecation. Severe constipation includes obstipation (failure to pass stools or gas) and fecal impaction, which can progress to bowel obstruction and become life-threatening.
=== Addiction === Mixed results have been seen in research into the use of antalarmin and other CRF-1 antagonists in the treatment of drug addiction disorders. Tests of antalarmin on cocaine use in cocaine-addicted monkeys produced only slight reductions of use that were not statistically significant; however, in tests on cocaine-addicted rats, antalarmin did prevent dose escalation with prolonged use, suggesting that it might stabilize cocaine use and prevent it increasing over time, although without consistently reducing it. Antalarmin also showed positive effects in reducing withdrawal syndrome from chronic opioid use, and significantly reduced self-administration of ethanol in ethanol-addicted rodents. Overall, additional research is needed to determine the therapeutic efficacy of antalarmin and other CRH non-peptide antagonists in anxiety, depression, inflammation, neurodegenerative disease, and addiction.
Gateway Distriparks Limited is an Indian logistics company based in Mumbai with three business verticals: container freight stations (CFS), inland container depots (ICD) with rail movement and cold chain storage and logistics. The company was founded in April 1994 and originally promoted by Newsprint Trading & Sales Corporation (NTSC), CWT Distribution Limited, NUR Investment and Trading Pvt. Ltd., and Intercontinental Forest Products Pte. Ltd. (IFP) as a joint venture company to conduct the business of warehousing, container freight stations and all related activities. As of November 2015, Prism International Private Limited (same group as NTSC) is the sole promoter of the company.
Sources: en.wikipedia.org
=== News Sources === Collier, Ben (18 July 2013), Becoming More Like The Culture, No. 1: Economics (v0.1), archived from the original on 22 July 2013, retrieved 5 August 2013 Cross, Tim (31 March 2017), "The novelist who inspired Elon Musk", The Economist, archived from the original on 21 May 2017, retrieved 4 April 2017. Newitz, Annalee (27 March 2017), "Elon Musk is setting up a company that will link brains and computers", Ars Technica.
Hemolysis or increased breakdown of red blood cells (for example hematoma resorption) Intrahepatic causes can be associated with elevated levels of conjugated bilirubin, unconjugated bilirubin or both. They include:
The above is just one example. There are other ways in which AMS is achieved; however, they all work based on improving mass selectivity and specificity by creating high kinetic energies before molecule destruction by stripping, followed by single-ion counting.
== External links == Metribolone at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Methyltrienolone - William Llewellyn's Anabolic.org Archived 2016-04-07 at the Wayback Machine
Sources: en.wikipedia.org
==== Seed-mediated growth ==== Seed-mediated growth is a synthetic method in which small, stable nuclei are grown in a separate chemical environment to a desired size and shape. Seed-mediated methods consist of two different stages: nucleation and growth. Variation of certain factors in the synthesis (e.g. ligand, nucleation time, reducing agent, etc.), can control the final size and shape of nanoparticles, making seed-mediated growth a popular synthetic approach to controlling morphology of nanoparticles. The nucleation stage of seed-mediated growth consists of the reduction of metal ions in a precursor to metal atoms. In order to control the size distribution of the seeds, the period of nucleation should be made short for monodispersity. The LaMer model illustrates this concept. Seeds typically consist small nanoparticles, stabilized by a ligand. Ligands are small, usually organic molecules that bind to the surface of particles, preventing seeds from further growth. Ligands are necessary as they increase the energy barrier of coagulation, preventing agglomeration. The balance between attractive and repulsive forces within colloidal solutions can be modeled by DLVO theory. Ligand binding affinity, and selectivity can be used to control shape and growth. For seed synthesis, a ligand with medium to low binding affinity should be chosen as to allow for exchange during growth phase. The growth of nanoseeds involves placing the seeds into a growth solution.
Data published by the Home Office shows a 25% rise in reported incidents of religious hate crime over the past 12 months, largely against Muslims and Jews as a result of the Gaza war. 11 October Office for National Statistics figures show the UK economy grew by 0.2% during August, following two months of stagnation. Virginia McCullough, who murdered her parents in 2019 then lived in the family home alongside their bodies for four years, is sentenced to life imprisonment with a minimum term of 36 years. 12 October Alex Salmond, former first minister of Scotland, dies aged 69 in North Macedonia. A woman in her 20s is reported to have died after going overboard from a cruise ship near the Channel Islands in the early hours. 15 October Five people, including two children, are killed in a crash on the M6 in Cumbria. Former Chelsea boss Thomas Tuchel agrees to become the next England manager. 16 October Office for National Statistics figures show that UK inflation decreased unexpectedly to 1.7% in the year to September, its lowest level in over three years. A suspected gas explosion destroys three houses in Benwell, Newcastle, killing a seven-year-old boy and a man in his thirties, and hospitalising six other people. The University of Oxford rejects former Prime Minister of Pakistan Imran Khan's application to become chancellor. 17 October The National Gallery has banned liquids, such as baby formula and milk, from its premises following a number of attacks on artworks.
LGD-4033 has not yet completed clinical development or been approved for any use. As of 2023, it is in phase 2 clinical trials for the treatment of hip fracture and muscle atrophy. LGD-4033 was developed by Ligand Pharmaceuticals, and is now being developed by Viking Therapeutics. Aside from its development as a potential pharmaceutical drug, LGD-4033 is on the World Anti-Doping Agency list of prohibited substances and is sold for physique- and performance-enhancing purposes by black-market Internet suppliers. LGD-4033 is often used in these contexts at doses greatly exceeding those evaluated in clinical trials, with unknown effectiveness and safety. Many products sold online that are purported to be LGD-4033 either contain none or contain other unrelated substances. Social media has played an important role in facilitating the widespread non-medical use of SARMs.
== Horticultural classification == This follows the classification adopted by V. Matthews in The International Clematis Register and Checklist 2002, except that C. ispahanica, now considered to have been included in error, has been omitted from the list of parent species in Tangutica Group.
=== Proton transfer reaction chamber === Proton transfer reaction mass spectrometry has traditionally used drift tubes as ion traps. However, radio frequency ion funnels offer an attractive alternative, as they improve compound specific sensitivity significantly. This is due to increasing the effective reaction time and focusing the ions. The same pressure ranges are required for ion funnels and drift tubes, so the technology is not difficult to implement. Ion funnels have been shown to favor transmission of ions with high m/z.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.